Anavex Life Sciences Corp. - Common Stock (AVXL)
2.7400
-1.4500 (-34.61%)
NASDAQ · Last Trade: Mar 25th, 11:39 PM EDT
Detailed Quote
| Previous Close | 4.190 |
|---|---|
| Open | 3.010 |
| Bid | 2.730 |
| Ask | 2.750 |
| Day's Range | 2.610 - 3.115 |
| 52 Week Range | 2.610 - 13.99 |
| Volume | 14,066,978 |
| Market Cap | 244.81M |
| PE Ratio (TTM) | -5.074 |
| EPS (TTM) | -0.5 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,743,619 |
Chart
About Anavex Life Sciences Corp. - Common Stock (AVXL)
Anavex Life Sciences is a biotechnology company focused on developing innovative therapeutic solutions for the treatment of neurodegenerative diseases and other central nervous system disorders. The company utilizes a unique approach to drug development that involves identifying compounds that can restore cellular health and brain function, aiming to alleviate the symptoms and progression of conditions such as Alzheimer’s disease and other cognitive disorders. Through rigorous research and clinical trials, Anavex strives to bring forward novel medications that enhance the quality of life for patients suffering from these challenging ailments. Read More
News & Press Releases
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.chartmill.com
Via Chartmill · March 25, 2026
Wednesday's session: top gainers and loserschartmill.com
Via Chartmill · March 25, 2026
Which stocks are gapping on Wednesday?chartmill.com
Via Chartmill · March 25, 2026
Wondering what's happening in today's pre-market session?chartmill.com
Via Chartmill · March 25, 2026
ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) Reports Q1 2026 Earnings Beat, Stock Gains in Pre-Marketchartmill.com
Via Chartmill · February 9, 2026

Anavex (AVXL) Q1 2026 Earnings Call Transcript
Via The Motley Fool · February 9, 2026
These stocks are moving in today's after hours sessionchartmill.com
Via Chartmill · January 13, 2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · January 6, 2026
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · December 30, 2025
LOS ANGELES, Dec. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) for violations of the securities laws.
By Schall Law · Via GlobeNewswire · December 24, 2025
LOS ANGELES, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) for violations of the securities laws.
By Schall Law · Via GlobeNewswire · December 17, 2025
Anavex said on Friday that the CHMP has indeed adopted a negative opinion “as expected.”
Via Stocktwits · December 12, 2025
LOS ANGELES, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) for violations of the securities laws.
By Schall Law · Via GlobeNewswire · December 10, 2025
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · December 3, 2025
Anavex (AVXL) Q4 2025 Earnings Call Transcript
Via The Motley Fool · November 25, 2025
Anavex ended the quarter with cash and cash equivalents of $102.6 million.
Via Stocktwits · November 25, 2025
Anavex Life Sciences stock surges after reporting a smaller-than-expected Q4 2025 loss, beating EPS estimates and boosting investor confidence.
Via Chartmill · November 25, 2025
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · November 19, 2025
The CHMP issued a negative trend vote but postponed its final decision to December.
Via Stocktwits · November 16, 2025
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Via Chartmill · November 14, 2025
Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · November 14, 2025
Via Benzinga · November 14, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Via Chartmill · November 14, 2025
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Via Chartmill · November 14, 2025